Literature DB >> 9174176

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.

P G Hoggard1, S Kewn, M G Barry, S H Khoo, D J Back.   

Abstract

Drugs commonly administered to patients infected with the human immunodeficiency virus (HIV) have been studied for their propensity to alter the intracellular phosphorylation of the anti-HIV nucleoside analog stavudine (2',3'-dideoxy-2',3'-didehydrothymidine; d4T) in peripheral blood mononuclear cells (PBMCs) and U937 cells in vitro. PBMCs isolated from the blood of healthy volunteers were stimulated by the mitogen phytohemagglutinin (10 microg/ml) for 72 h. Stimulated PBMCs (3 x 10(6) cells/plate) were then incubated with [3H]d4T (0.65 microCi; 3 microM) and either acyclovir, dapsone, ddC, ddI, fluconazole, foscarnet, ganciclovir, itraconazole, lobucavir, ranitidine, ribavirin, rifampin, sorivudine, sulfamethoxazole, trimethoprim, lamivudine (3TC), zidovudine, or thymidine (30 and 300 microM) for 24 h. Doxorubicin and drugs showing some evidence of inhibition were also studied at 0.3 and 3 microM. Cells were extracted overnight with 60% methanol prior to analysis by radiometric high-performance liquid chromatography. Additional data for nine of the drugs were obtained by incubation with [3H]d4T in U937 cells for 24 h. The effect of d4T (0.2 to 20 microM) on zidovudine (0.65 microCi; 0.018 microCi) phosphorylation was also studied. Zidovudine significantly reduced d4T total phosphates in PBMCs and U937 cells (in PBMCs to 33% [P < 0.001] and 17% [P < 0.001] of that in control cells at 3 and 30 microM, respectively). A small reduction in zidovudine phosphorylation was seen with d4T but only at d4T:zidovudine ratios of 100 and 1,000. Of the other compounds screened, only thymidine, ribavirin, and doxorubicin produced inhibition of d4T phosphorylation in both PBMCs and U937 cells. However, doxorubicin was cytotoxic at 3 microM. The decrease in d4T phosphorylation in the presence of ribavirin is consistent with previous findings with zidovudine. Although ddC significantly inhibited the phosphorylation of d4T in PBMCs, this was not seen in U937 cells, and it is probable that the findings in PBMCs are related to mitochondrial toxicity [based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide cytotoxicity assay]. The only drugs screened which may interfere with d4T phosphorylation at clinically relevant concentrations were zidovudine, ribavirin, and doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174176      PMCID: PMC163892          DOI: 10.1128/AAC.41.6.1231

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites.

Authors:  M G Barry; S H Khoo; G J Veal; P G Hoggard; S E Gibbons; E G Wilkins; O Williams; A M Breckenridge; D J Back
Journal:  AIDS       Date:  1996-10       Impact factor: 4.177

2.  Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation.

Authors:  G J Veal; P G Hoggard; M G Barry; S Khoo; D J Back
Journal:  AIDS       Date:  1996-05       Impact factor: 4.177

3.  Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses.

Authors:  P Kremers; J Duvivier; C Heusghem
Journal:  J Clin Pharmacol       Date:  1974 Feb-Mar       Impact factor: 3.126

4.  Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

Authors:  M Baba; R Pauwels; P Herdewijn; E De Clercq; J Desmyter; M Vandeputte
Journal:  Biochem Biophys Res Commun       Date:  1987-01-15       Impact factor: 3.575

5.  Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.

Authors:  S Eksborg; H Ehrsson; I Andersson
Journal:  J Chromatogr       Date:  1979-12-01

6.  Fluoxetine kinetics and protein binding in normal and impaired renal function.

Authors:  G R Aronoff; R F Bergstrom; S T Pottratz; R S Sloan; R L Wolen; L Lemberger
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

7.  Drug interactions with zidovudine phosphorylation in vitro.

Authors:  P G Hoggard; G J Veal; M J Wild; M G Barry; D J Back
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

8.  Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.

Authors:  G J Veal; M J Wild; M G Barry; D J Back
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

9.  Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.

Authors:  D P Merrill; M Moonis; T C Chou; M S Hirsch
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

10.  Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

Authors:  H W Murray; K E Squires; W Weiss; S Sledz; H S Sacks; J Hassett; A Cross; R E Anderson; L M Dunkle
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

View more
  37 in total

1.  The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.

Authors:  S Kewn; P G Hoggard; S D Sales; M A Johnson; D J Back
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

2.  Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.

Authors:  J M de Muys; H Gourdeau; N Nguyen-Ba; D L Taylor; P S Ahmed; T Mansour; C Locas; N Richard; M A Wainberg; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 3.  Stavudine once daily.

Authors:  Susan M Cheer; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

Review 5.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

6.  Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.

Authors:  P G Hoggard; V Manion; M G Barry; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

7.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.

Authors:  H Ma; S Le Pogam; S Fletcher; F Hinojosa-Kirschenbaum; H Javanbakht; J-M Yan; W-R Jiang; N Inocencio; K Klumpp; I Nájera
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 9.  Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Authors:  Nila Bhana; Douglas Ormrod; Caroline M Perry; David P Figgitt
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 10.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.